Real-World Comparative Effectiveness of Vedolizumab Versus Upadacitinib for Crohn’s Disease Through 52 Weeks
In this tertiary-center cohort, upadacitinib produced faster clinical response at 12 weeks, but SFCR, durability, and safety profiles were similar through 52 weeks.
Authors
- Grace Hardwick
- Lindsay Clarke (ORCID: https://orcid.org/0009-0005-8088-5025)
- Rahul S. Dalal (ORCID: https://orcid.org/0000-0003-4622-8441)
- Jessica Ravikoff Allegretti (ORCID: https://orcid.org/0000-0003-3585-2425)
- Heidy Cabral
- Alex Carlin
Institutions
- Brigham and Women's Hospital (US)
Publication Details
- Journal
- Journal of Clinical Gastroenterology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1097/mcg.0000000000002309
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00